2023
Impact of sex on Transcatheter aortic valve replacement outcomes: Results of a single-center study
See C, Wang Y, Yang Y, Tirziu D, Papoutsidakis N, Francese D, Kaple R, Cleman M, Lansky A, Forrest J. Impact of sex on Transcatheter aortic valve replacement outcomes: Results of a single-center study. International Journal Of Cardiology 2023, 398: 131643. PMID: 38065329, DOI: 10.1016/j.ijcard.2023.131643.Peer-Reviewed Original ResearchNew-generation valvesTranscatheter Aortic Valve Replacement OutcomesImpact of sexTAVR outcomesArtery diseaseYale-New Haven HospitalSTS mortality scorePeripheral artery diseaseSingle-center studyCoronary artery diseaseKaplan-Meier curvesLog-rank testNew Haven HospitalSex-based disparitiesSignificant differencesCardiovascular comorbiditiesSAPIEN 3Transfemoral accessSAPIEN XTConsecutive patientsCox modelingMortality scoreEvolut RFemale sexEvolut PROImpact of New-Onset Conduction Disturbances following Transcatheter Aortic Valve Replacement on Outcomes: A Single-Center Study
See C, Wang Y, Huang H, Parise H, Yang Y, Tirziu D, Francese D, Papoutsidakis N, Bader E, Kaple R, Cleman M, Lansky A, Forrest J. Impact of New-Onset Conduction Disturbances following Transcatheter Aortic Valve Replacement on Outcomes: A Single-Center Study. Journal Of Interventional Cardiology 2023, 2023: 5390338. PMID: 37292113, PMCID: PMC10247319, DOI: 10.1155/2023/5390338.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve replacementNew-onset conduction disturbancesAortic valve replacementPersistent conduction disturbancesConduction disturbancesValve replacementSurgical aortic valve replacementSingle-center retrospective analysisYale-New Haven HospitalSingle-center studyCause mortality ratesCause mortality riskLong-term outcomesNew Haven HospitalPeriprocedural factorsAortic stenosisConsecutive patientsTAVR proceduresTerm outcomesRetrospective analysisMortality riskMortality ratePatientsOutcomesPatient's ECGColchicine and high-intensity rosuvastatin in the treatment of non-critically ill patients hospitalised with COVID-19: a randomised clinical trial
Shah T, McCarthy M, Nasir I, Archer H, Ragheb E, Kluger J, Kashyap N, Paredes C, Patel P, Lu J, Kandel P, Song C, Khan M, Huang H, Haq F, Ahmad R, Howes C, Cambi B, Lancaster G, Cleman M, Dela Cruz C, Parise H, Lansky A. Colchicine and high-intensity rosuvastatin in the treatment of non-critically ill patients hospitalised with COVID-19: a randomised clinical trial. BMJ Open 2023, 13: e067910. PMID: 36828654, PMCID: PMC9971831, DOI: 10.1136/bmjopen-2022-067910.Peer-Reviewed Original ResearchConceptsStandard of careHigh-intensity rosuvastatinElectronic medical recordsCOVID-19 diseaseMedical recordsPrimary endpointThromboembolic eventsYale New Haven Health SystemSevere COVID-19 diseaseCOVID-19Prespecified primary endpointVenous thromboembolic eventsRisk of progressionCombination of colchicineSafety monitoring boardCare armHispanics/LatinosTherapeutic anticoagulationIndex hospitalisationIll patientsMedian ageFuture trialsEffect of colchicineClinical trialsMonitoring board
2022
Outcomes of the Novel Supreme Drug-Eluting Stent in Complex Coronary Lesions: A PIONEER III Substudy
Patel K, Lansky A, Kereiakes D, Windecker S, Cristea E, Pietras C, Dressler O, Issever M, Curtis M, Bertolet B, Zidar J, Smits P, Díaz V, McLaurin B, Brogno D, Janssens L, Vrolix M, Gómez-Blázquez I, Sahul Z, Kabour A, Salido L, Cleman M, Saito S, Leon M, Baumbach A, Investigators I. Outcomes of the Novel Supreme Drug-Eluting Stent in Complex Coronary Lesions: A PIONEER III Substudy. Journal Of The Society For Cardiovascular Angiography & Interventions 2022, 1: 100004. PMID: 39130138, PMCID: PMC11308031, DOI: 10.1016/j.jscai.2021.100004.Peer-Reviewed Original ResearchDrug-eluting stentsTarget lesion failureDP-EESComplex lesionsLesion failureAdverse eventsLesion complexityMajor adverse cardiac eventsSingle-blind clinical trialEnd pointAdverse cardiac eventsChronic coronary syndromePrimary end pointSecondary end pointsTarget lesion revascularizationTarget vessel failureComplex coronary lesionsPercutaneous coronary interventionEverolimus-eluting stentsDrug eluting stentsHigh rateLesion revascularizationCoronary syndromeCardiac eventsCoronary intervention
2021
Impact of Persistent vs. Transient Conduction Abnormalities Within 7 Days Post-TAVR on Mortality: Results of a Single-Center Prospective Registry
See C, Wang Y, Yang Y, Tirziu D, Papoutsidakis N, Kaple R, Cleman M, Lansky A, Forrest J. Impact of Persistent vs. Transient Conduction Abnormalities Within 7 Days Post-TAVR on Mortality: Results of a Single-Center Prospective Registry. Cardiovascular Revascularization Medicine 2021, 28: s43. DOI: 10.1016/j.carrev.2021.06.099.Peer-Reviewed Original ResearchIMPACT OF SEX ON OUTCOMES IN TAVR: RESULTS FROM A SINGLE CENTER PROSPECTIVE REGISTRY
Wang Y, Yang Y, See C, tirziu D, Papoutsidakis N, Kaple R, Cleman M, Lansky A, Forrest J. IMPACT OF SEX ON OUTCOMES IN TAVR: RESULTS FROM A SINGLE CENTER PROSPECTIVE REGISTRY. Journal Of The American College Of Cardiology 2021, 77: 900. DOI: 10.1016/s0735-1097(21)02259-2.Peer-Reviewed Original ResearchIMPACT OF PACEMAKER IMPLANT ≤ 30 DAYS POST TAVR ON MORTALITY: RESULTS OF A SINGLE CENTER PROSPECTIVE REGISTRY
See C, Wang Y, Yang Y, Tirziu D, Papoutsidakis N, Kaple R, Cleman M, Lansky A, Forrest J. IMPACT OF PACEMAKER IMPLANT ≤ 30 DAYS POST TAVR ON MORTALITY: RESULTS OF A SINGLE CENTER PROSPECTIVE REGISTRY. Journal Of The American College Of Cardiology 2021, 77: 974. DOI: 10.1016/s0735-1097(21)02333-0.Peer-Reviewed Original Research